Bgm (BGM) Non-Current Assets (2019 - 2025)
Bgm (BGM) posted quarterly Non-Current Assets of $382.3 million for Q3 2025, up 21911.37% year-over-year from N/an in Q3 2024, and up 132.45% quarter-over-quarter from $164.5 million in Q1 2025.
Bgm (BGM) Non-Current Assets (2019 - 2025) Analysis & Trends
Bgm (BGM) has reported Non-Current Assets for 7 consecutive years, with $382.3 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Non-Current Assets rose 21911.37% year-over-year to $382.3 million; the TTM figure through Sep 2025 stood at -$27078.7 billion (down 1559220761.62% YoY), while the FY2025 annual figure was $382.3 million, up 21911.37% from the prior year.
- Non-Current Assets improved to $382.3 million in Q3 2025 per BGM's latest filing, from $164.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $382.3 million in Q3 2025 and bottomed at -$58505.6 billion in Q1 2021.
- Historically, Non-Current Assets has averaged -$12852.1 billion across 5 years, with a median of $9.1 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 95.69% — and 2025, when it surged 21911.37%.
- Bgm's Non-Current Assets stood at $35.0 million in 2021, then fell by 1.42% to $34.5 million in 2022, then plunged by 95.69% to $1.5 million in 2023, then climbed by 16.88% to $1.7 million in 2024, then soared by 21911.37% to $382.3 million in 2025.
- Business Quant data shows BGM's Non-Current Assets at $382.3 million in Q3 2025, $164.5 million in Q1 2025, and $1.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Bgm | 29.89 Mn | 20.07 Mn | - | 382.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 382.27 Mn |
| Mar 31, 2025 | 164.45 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 16.53 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | -27,079.30 Bn |
| Sep 30, 2022 | 34.49 Mn |
| Mar 31, 2022 | -42,936.45 Bn |
| Sep 30, 2021 | 34.99 Mn |
| Mar 31, 2021 | -58,505.61 Bn |
| Sep 30, 2020 | 10.63 Mn |
| Sep 30, 2019 | 10.30 Mn |